{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:17:04Z","timestamp":1791821824453,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01-BC 0006161"],"award-info":[{"award-number":["Z01-BC 0006161"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01-BC 006150"],"award-info":[{"award-number":["Z01-BC 006150"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["Z01-BC 0006161"],"award-info":[{"award-number":["Z01-BC 0006161"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jmb.2026.169841","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:21:45Z","timestamp":1777929705000},"page":"169841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads"],"prefix":"10.1016","volume":"438","author":[{"given":"Yves","family":"Pommier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2026.169841_b0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jmb.2026.169841_b0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrd3404","article-title":"Interfacial inhibitors: targeting macromolecular complexes","volume":"11","author":"Pommier","year":"2011","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2026.169841_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169401","article-title":"Targeting DNA topoisomerase I for the treatment of cancer: past, present and future","volume":"438","author":"Venkatachalam","year":"2026","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2555920","article-title":"DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts","volume":"246","author":"Giovanella","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jmb.2026.169841_b0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-019-03987-z","article-title":"PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity","volume":"85","author":"Fontaine","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169841_b0035","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1038\/s41467-025-64509-5","article-title":"Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase I trial of gapped scheduling","volume":"16","author":"Thomas","year":"2025","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169841_b0040","article-title":"Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity","volume":"3","author":"Gayle","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.jmb.2026.169841_b0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.jmb.2026.169841_b0050","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jmb.2026.169841_b0055","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","article-title":"TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor","volume":"21","author":"Jo","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0060","first-page":"2","article-title":"Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters","volume":"9","author":"Roth","year":"2026","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jmb.2026.169841_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3727\/095535490820873912","article-title":"10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells","volume":"2","author":"O'Connor","year":"1990","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jmb.2026.169841_b0070","first-page":"753","article-title":"Camptothecin and taxol: discovery to clinic \u2013 thirteenth Bruce F. Cain memorial award lecture","volume":"55","author":"Wall","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0075","first-page":"168","article-title":"Topoisomerase inhibitors: why develop new ones","volume":"1","author":"Pommier","year":"1999","journal-title":"Opin. Oncol. Endocrine Metabolic Investig. Drugs"},{"key":"10.1016\/j.jmb.2026.169841_b0080","doi-asserted-by":"crossref","first-page":"10325","DOI":"10.1021\/bi00200a013","article-title":"Differential interactions of camptothecin lactone and carboxylate forms with human blood components","volume":"33","author":"Mi","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2026.169841_b0085","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1021\/jm980400l","article-title":"Homocamptothecins: synthesis and antitumor activity of novel E-ring- modified camptothecin analogues","volume":"41","author":"Lavergne","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0090","first-page":"6577","article-title":"Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations","volume":"60","author":"Urasaki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0095","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jmb.2026.169841_b0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00280-025-04778-5","article-title":"Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas","volume":"95","author":"O'Sullivan Coyne","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169841_b0110","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1535-7163.MCT-08-0706","article-title":"The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives","volume":"8","author":"Pommier","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2019.05.074","article-title":"Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors","volume":"178","author":"Tang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0120","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1021\/bi1009419","article-title":"A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces g2\/m phase cell cycle arrest to k562 cells","volume":"49","author":"Wu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2026.169841_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105789","article-title":"Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity","volume":"123","author":"Yang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0135","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/MCB.20.11.3977-3987.2000","article-title":"Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff","volume":"20","author":"Strumberg","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0140","first-page":"6365","article-title":"Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells","volume":"49","author":"Holm","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0145","first-page":"5077","article-title":"Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nsmb.2258","article-title":"Topoisomerase I poisoning results in PARP-mediated replication fork reversal","volume":"19","author":"Ray Chaudhuri","year":"2012","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15252\/embr.201540964","article-title":"SLFN11 inhibits checkpoint maintenance and homologous recombination repair","volume":"17","author":"Mu","year":"2016","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jmb.2026.169841_b0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmb.2026.169841_b0165","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015654118","article-title":"SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors","volume":"118","author":"Jo","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169841_b0170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41556-025-01852-1","article-title":"RPA exhaustion activates SLFN11 to eliminate cells with heightened replication stress","volume":"28","author":"Stanage","year":"2026","journal-title":"Nature Cell Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0175","doi-asserted-by":"crossref","first-page":"11029","DOI":"10.1038\/s41467-025-66068-1","article-title":"SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress","volume":"16","author":"Coleman","year":"2025","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169841_b0180","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.celrep.2020.02.117","article-title":"Chromatin remodeling and immediate early gene activation by SLFN11 in response to replication stress","volume":"30","author":"Murai","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.jmb.2026.169841_b0185","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1126\/science.adh7950","article-title":"DNA damage induces p53-independent apoptosis through ribosome stalling","volume":"384","author":"Boon","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jmb.2026.169841_b0190","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.molcel.2025.01.008","article-title":"SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis","volume":"85","author":"Ogawa","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmb.2026.169841_b0195","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1038\/s41467-024-54833-7","article-title":"Phosphorylation-mediated conformational change regulates human SLFN11","volume":"15","author":"Kugler","year":"2024","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169841_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature11433","article-title":"Codon-usage-based inhibition of HIV protein synthesis by human Schlieffen 11","volume":"491","author":"Li","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169841_b0205","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","article-title":"DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs","volume":"25","author":"Li","year":"2018","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0210","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1038\/s41467-022-33123-0","article-title":"Mechanistic understanding of human SLFN11","volume":"13","author":"Metzner","year":"2022","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169841_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adj5465","article-title":"Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA","volume":"9","author":"Zhang","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jmb.2026.169841_b0220","article-title":"SLFN11 puts the brakes on alternative lengthening of telomeres","author":"Khandagale","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jmb.2026.169841_b0225","article-title":"SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres","author":"Segura-Bayona","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jmb.2026.169841_b0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169841_b0235","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169841_b0240","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169841_b0245","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmb.2026.169841_b0250","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/s41388-024-03094-1","article-title":"Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks","volume":"43","author":"Onji","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.jmb.2026.169841_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184601","article-title":"Precision oncology with drugs targeting the replication stress, ATR, and Schlafen 11","volume":"13","author":"Jo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmb.2026.169841_b0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0265","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1097\/PAS.0000000000002299","article-title":"Immunohistochemical evaluation of Schlafen 11 (SLFN11) expression in cancer in the search of biomarker-informed treatment targets: a study of 127 entities represented by 6658 tumors","volume":"48","author":"Kaczorowski","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jmb.2026.169841_b0270","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0026-895X(25)10121-1","article-title":"Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin","volume":"34","author":"Eng","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169841_b0275","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.85.20.7501","article-title":"DNA topoisomerase-targeting antitumor drugs can be studied in yeast","volume":"85","author":"Nitiss","year":"1988","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169841_b0280","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/1535-7163.MCT-13-0551","article-title":"Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel","volume":"13","author":"Maede","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0285","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-19-0419","article-title":"The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib","volume":"25","author":"Marzi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058239","article-title":"ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells","volume":"8","author":"Alagoz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2026.169841_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104058","article-title":"Somatic and germline ATM variants in non-small-cell lung cancer: therapeutic implications","volume":"188","author":"Hernandez-Martinez","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jmb.2026.169841_b0300","doi-asserted-by":"crossref","first-page":"44945","DOI":"10.1074\/jbc.M111.299347","article-title":"DNA repair factor MRE11\/RAD50 cleaves 3\u2032-phosphotyrosyl bonds and resects DNA to repair damage caused by topoisomerase 1 poisons","volume":"286","author":"Sacho","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0305","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1093\/nar\/gku088","article-title":"PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage","volume":"42","author":"Das","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169841_b0310","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/10985549.2025.2555891","article-title":"PARP1-dependent and independent pathways for resolution of trapped topoisomerase I covalent complexes","volume":"45","author":"Das","year":"2025","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0315","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0320","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2026.169841_b0325","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Nogales","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmb.2026.169841_b0330","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-17-0443","article-title":"Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors","volume":"24","author":"Tang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmb.2026.169841_b0335","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmb.2026.169841_b0340","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1074\/jbc.M106287200","article-title":"S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function","volume":"277","author":"Cliby","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0345","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1074\/jbc.M411890200","article-title":"The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons","volume":"280","author":"Flatten","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169841_b0350","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0355","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0360","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2026.169841_b0365","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jmb.2026.169841_b0370","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition","volume":"349","author":"Murai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jmb.2026.169841_b0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nsmb.2501","article-title":"Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition","volume":"20","author":"Berti","year":"2013","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169841_b0380","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","article-title":"The development of ATM inhibitors in cancer therapy","volume":"20","author":"Ampolini","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jmb.2026.169841_b0385","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13543776.2024.2446228","article-title":"Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003-present)","volume":"35","author":"Ivanenkov","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jmb.2026.169841_b0390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2026.169841_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020221","article-title":"Recent technological and intellectual property trends in antibody-drug conjugate research","volume":"16","author":"Choi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jmb.2026.169841_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"G\u00e9raud","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jmb.2026.169841_b0405","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2026.169841_b0410","doi-asserted-by":"crossref","first-page":"D1097","DOI":"10.1093\/nar\/gkad831","article-title":"ADCdb: the database of antibody-drug conjugates","volume":"52","author":"Shen","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169841_b0415","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","article-title":"Dual-payload ADCs move into first oncology clinical trials","volume":"24","author":"Mullard","year":"2025","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2026.169841_b0420","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1158\/1078-0432.CCR-14-2112","article-title":"SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing's sarcoma","volume":"21","author":"Tang","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626002147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626002147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:52:13Z","timestamp":1783086733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283626002147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":84,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022283626002147"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2026.169841","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2026.169841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"169841"}}